Home・Akciju saraksts・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

14.93 2.47

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.47

Max

14.8

Galvenie mērījumi
By Trading Economics
Ienākumi	-176M 34M
Pārdošana	591K 78M
P/E Sektora vidējais	7.112 64.641
EPS	0.25
Peļņas marža	44.212
Darbinieki	128
EBITDA	2.7M 50M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+7.55% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-92M 2B
Iepriekšējā atvēršanas cena	12.46
Iepriekšējā slēgšanas cena	14.93

Ziņu noskaņojums

By Acuity

50%

151 / 340 Rangs Healthcare

Aurinia Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

2026. g. 1. aug. 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

2026. g. 31. jūl. 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

2026. g. 29. jūl. 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

2026. g. 28. jūl. 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

2026. g. 27. jūl. 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

2026. g. 24. jūl. 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

2026. g. 22. jūl. 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

2026. g. 21. jūl. 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

2026. g. 20. jūl. 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Salīdzinājums

Cenas izmaiņa

Aurinia Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

7.55% augšup

Prognoze 12 mēnešiem

Vidējais 15.67 USD 7.55%

Augstākais 17 USD

Zemākais 15 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Aurinia Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Aurinia Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

151 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.